Skip to content

Author

A. Azar

We have 1 of 6 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

RNA terminal uridylyl transferases are druggable vulnerabilities in AML but are dispensable for normal hematopoiesis

Together, these findings identify TUT4/7 as druggable targets, whose inactivation suppresses AML while sparing normal hematopoiesis, and represents a promising therapeutic strategy in combination with venetoclax.

Christopher Mapperley, Elise Georges, A. Azar et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.